Apr 1981 Joined Otsuka Pharmaceutical Co., Ltd. Jan 1993 Head, San Francisco Office, Otsuka America Pharmaceutical Inc. Nov 1995 Head, Otsuka Maryland Research Laboratories, Otsuka America Pharmaceutical Inc. Jun 2000 Executive Officer, in charge of Research (overseeing Japan and U.S.), Otsuka Pharmaceutical Co., Ltd. Jun 2004 Executive Officer, Deputy Director, Otsuka Frankfurt Research Institute GmbH, Otsuka Pharmaceutical Co., Ltd. Jan 2006 Managing Executive Officer, in charge of Global Pharmaceutical Business Development, Otsuka Pharmaceutical Co., Ltd. Feb 2007 Senior Managing Executive Officer, in charge of Global Tuberculosis Business, Otsuka Pharmaceutical Co., Ltd. Dec 2018 Representative Director, President, the Company Oct 2023 CEO, J-Pharma USA, Inc. Jun 2026 Representative Director, President and CEO, the Company (current)

Apr 2005 Joined ZS Associates, Tokyo Office Jul 2009 Transferred to ZS Associates, Los Angeles Office Jul 2010 Transferred to ZS Associates, Tokyo Office Jul 2011 General Manager, BI Business Development, Business Development Department, Otsuka Pharmaceutical Co., Ltd. Mar 2013 M3, Inc., New Business Development Department Jun 2013 Founder and Representative Director, Zpeer, Inc. Jun 2018 Founder and CEO, VetScope, Inc. (U.S.) Jan 2020 Founder and CEO, VetScope Pte. Ltd. (Singapore) Apr 2023 Interim CFO, the Company Jun 2023 Director, Chief Financial Officer, the Company Oct 2023 CFO and Secretary, J-Pharma USA, Inc. Jun 2026 Director, CFO, the Company (current)

Apr 1995 Joined U.S. National Cancer Institute Dec 2005 Joined Takeda Pharmaceutical Company Limited Jul 2014 Joined With Partners Inc. Oct 2018 Managing Partner, TM Partners LLC (current) Oct 2018 Investment Partner, Newton Biocapital SA Mar 2019 Outside Director, Edit Force, Inc. (current) Jun 2019 Outside Director, Ribomic Inc. Jan 2020 Deputy Program Leader, "Kusuri no Silicon Valley TOYAMA" Creation Consortium (current) Jun 2020 Outside Director, the Company Apr 2021 Director, J-Biosciences, Inc. Oct 2023 Outside Director (Audit and Supervisory Committee Member), the Company (current) Mar 2025 Outside Audit & Supervisory Board Member, Felix Inc. (current)

Oct 1995 Joined Chuo Audit Corporation Apr 2004 Joined Shimizu International Patent Office (now Symphonia Intellectual Property Office) Jun 2004 Outside Audit & Supervisory Board Member, Longreach Group Co., Ltd. (current) Feb 2010 Established Tajima Certified Public Accountant Office; Representative (current) Sep 2014 Outside Audit & Supervisory Board Member, PRISM Pharma Co., Ltd. (now PRISM BioLab Co., Ltd.) Sep 2014 Supervisory Executive Officer, Tosei Reit Investment Corporation (current) Sep 2014 Outside Audit & Supervisory Board Member, Oncotherapy Science, Inc. (current) Aug 2015 Auditor, Iida Foundation (general incorporated foundation) (current) Dec 2015 Established Tajima Accounting Office Co., Ltd.; Representative Director (current) Jan 2016 Outside Audit & Supervisory Board Member, Edigene Inc. (now Modalis Therapeutics Corporation) Mar 2016 Outside Audit & Supervisory Board Member, Lena Therapeutics Co., Ltd. (current) Jun 2016 Outside Audit & Supervisory Board Member, First Kitchen Co., Ltd. (current) Jun 2016 Outside Audit & Supervisory Board Member, Wendy's Japan Co., Ltd. (current) Dec 2016 Outside Audit & Supervisory Board Member, Obunsha Co., Ltd. (current) Aug 2018 Outside Director (Audit and Supervisory Committee Member), Edigene Inc. (now Modalis Therapeutics Corporation) (current) Sep 2018 Outside Audit & Supervisory Board Member, NewGen Pharma Inc. (current) Jan 2019 Outside Director (Audit Committee Member), Fujitsu Component Limited (now FCL Components Limited) (current) Feb 2021 Outside Audit & Supervisory Board Member, the Company Mar 2021 Outside Audit & Supervisory Board Member, Tabata Co., Ltd. (current) Jan 2023 Audit & Supervisory Board Member, Longreach Business Partners Co., Ltd. (current) Jun 2023 Outside Audit & Supervisory Board Member, Matsuya Foods Holdings Co., Ltd. (current) Aug 2023 Outside Audit & Supervisory Board Member, nobitel Co., Ltd. (current) Oct 2023 Outside Director (Audit and Supervisory Committee Member), the Company (current) Jul 2024 Outside Audit & Supervisory Board Member, Shin Nihon Sumai Co., Ltd. (current) Mar 2025 Outside Audit & Supervisory Board Member, Shin Nihon Sumai Holdings Co., Ltd. (current)

Apr 2003 Joined Racesum Research Co., Ltd. Sep 2008 Attorney, Kitamura, Kato & Sano Law Office (current) Jun 2022 Outside Director (Audit and Supervisory Committee Member), Logly Inc. (current) Nov 2022 Outside Audit & Supervisory Board Member, Kukureb Advisors Co., Ltd. (current) Jun 2023 Outside Audit & Supervisory Board Member, the Company Oct 2023 Outside Director (Audit and Supervisory Committee Member), the Company (current)

Apr 2004 Joined Eisai Co., Ltd. Apr 2013 Regional Manager, Asia Regional Promotion Office, Eisai Co., Ltd. Sep 2013 Senior Project Manager and Brand Team Leader, Neuroscience Area, AbbVie GK May 2014 Manager, ASEAN, Santen Pharmaceutical Co., Ltd. Apr 2016 President, Santen Pharmaceutical Asia Pte. Ltd. Sep 2018 Deputy General Manager, Santen Pharmaceutical (China) Co., Ltd. Feb 2019 Executive Officer and Head of Business Division (Japan and Asia), SanBio Co., Ltd. Sep 2019 Founder and Representative Executive Member, H&L G.K. (predecessor of Eighty-Eighty Therapeutics) Jan 2022 Managing Director and Asia Representative, Locust Walk Partners, LLC (current) Sep 2023 Representative Director, Eighty-Eighty Therapeutics Co., Ltd. (current) Apr 2024 Outside Director, FREST Inc. (current) Jan 2025 Director, Blisxia Co., Ltd. (current) Jun 2026 Director, CBO, the Company (current)

Apr 1993 Joined Goldman Sachs Securities Co., Ltd. Jul 1994 Joined Merrill Lynch Japan Securities Co., Ltd. (now BofA Securities Japan Co., Ltd.) Feb 2007 Managing Director, Equity Capital Markets Department, Merrill Lynch Japan Securities Co., Ltd. Mar 2012 Managing Director and Head of Equity Capital Markets Department, Capital Markets Division, BofA Securities Japan Co., Ltd. Nov 2015 Joined Mizuho Securities Co., Ltd.; Director, Financial Strategy Department, Equity Group Apr 2016 General Manager, Equity Capital Markets First Department, Products Division, Mizuho Securities Co., Ltd. Apr 2018 Senior Executive, Investment Banking Division, Mizuho Securities Co., Ltd. Jul 2019 Joined J.P. Morgan Securities Japan Co., Ltd.; Managing Director, Equity Capital Markets Department, Investment Banking Division Dec 2021 Outside Director (Audit and Supervisory Committee Member), Retty Inc. (current) May 2022 Executive Officer and General Manager, Corporate Communications Division, Premier Anti-Aging Co., Ltd. (current) Jun 2024 Outside Director, NetOne Systems Co., Ltd. Jun 2026 Outside Director, the Company (current)